go to homepage

Wondfo’s WELLlife COVID-19/Influenza A&B test receives Emergency Use Authorization (EUA).

Wondfo’s WELLlife COVID-19/Influenza A&B Test Receives Emergency Use Authorization (EUA)

We are proud to announce that Wondfo’s WELLlife COVID-19/Influenza A&B Test has officially received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). This milestone highlights our commitment to delivering reliable and innovative diagnostic solutions in the fight against respiratory illnesses.


About the WELLlife COVID-19/Influenza A&B Test

The test distinguishes between SARS-CoV-2, Influenza A, and Influenza B with a single nasal swab, providing rapid and accurate results in just 10 minutes. This makes it an essential tool for maintaining a safe and healthy environment.

Our collaboration with DCN Dx, a leading contract research organization for in vitro diagnostics, through the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech program ensures the highest level of quality, accuracy, and reliability in our tests.


Key Features of the WELLlife Test

  1. Dual Detection
    • Differentiates between COVID-19, Influenza A, and Influenza B, helping streamline diagnosis during overlapping flu and COVID-19 seasons.
  2. Fast Results
    • Provides reliable results in a matter of minutes, enabling prompt decision-making.
  3. High Sensitivity and Specificity
    • Meets rigorous standards for accuracy, ensuring trust in every test result.
  4. User-Friendly Design
    • Easy to use, making it suitable for point-of-care settings and healthcare professionals.

Why EUA Approval Matters

The FDA’s Emergency Use Authorization (EUA) is granted to products that meet stringent safety, performance, and reliability criteria during public health emergencies. With this EUA, the WELLlife test is recognized as a trusted tool in managing respiratory illness diagnostics during critical times.


How the WELLlife Test Supports Public Health

  1. Streamlines Diagnosis
    • Differentiating between COVID-19 and influenza is vital for appropriate treatment and containment strategies.
  2. Reduces Strain on Healthcare Systems
    • Quick and accurate results help minimize unnecessary testing and allow healthcare providers to prioritize resources effectively.
  3. Empowers Healthcare Professionals
    • Provides actionable insights, ensuring patients receive timely and targeted care.

Partner with Wondfo for Reliable Diagnostics

With the EUA-approved WELLlife COVID-19/Influenza A&B Test, Wondfo continues to support global efforts in combating respiratory illnesses. Our dedication to innovation and quality ensures that you have the tools needed to make informed decisions and protect public health.

Contact us today to learn more about the WELLlife test and how it can enhance your diagnostic capabilities. Together, we can make a difference. 🌟

Post Tags :

Share :